Skip to main content

Table 4 Predictors of direct medical cost for prostate cancer during the first 12 months post-diagnosis

From: National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period: a nationwide population-based study using a national health insurance database

Variables Unadjusted Adjusted
Coefficient P value Coefficient P value
Age, years −0.0067 <.0001 −0.0015 <.0001
Income level, quintile
 Below poverty line (lowest)
 I 0.0012 0.9142 −0.0241 0.0144
 II 0.0070 0.5280 −0.0306 0.0025
 III 0.0297 0.0045 −0.0074 0.4403
 IV 0.0267 0.0071 −0.0136 0.1357
 V (highest) 0.0335 0.0003 0.0090 0.2886
Residential area
 Metropolitan
 Urban 0.0023 0.6586 0.0055 0.2516
 Rural −0.0092 0.16 0.0156 0.0092
Charlson comorbidity index
 0
 1–2 0.0639 <.0001 0.0715 <.0001
 3–4 0.1377 <.0001 0.1572 <.0001
 ≥ 5 0.1791 <.0001 0.1957 <.0001
Primary treatment
 Surgery only
 Surgery+ADT 0.2549 <.0001 0.2570 <.0001
 Surgery+RT 0.3352 <.0001 0.3403 <.0001
 Surgery+ADT + RT 0.7928 <.0001 0.7961 <.0001
 RT only 0.5093 <.0001 0.4997 <.0001
 ADT only −0.1133 <.0001 −0.1051 <.0001
 ADT + RT 0.5354 <.0001 0.5421 <.0001
Adjusted-R    0.1812  
  1. ADT Androgen deprivation therapy, RT Radiotherapy, Multivariable adjusted models were adjusted for age, income level, residential area, Charlson comorbidity index, and primary treatment type